茄子种子衍生的西洛格卢干通过肠道微生物群减轻小鼠的胰岛素抵抗
Jingrui Yang1, Huizi Tan1, Xiaomao Peng1
1State Key Laboratory of Food Science and TechnologyResources, China-Canada Joint Lab of Food Science and Technology (Nanchang), Nanchang University, 235 Nanjing East Road, Nanchang 330047, China.
Journal of agricultural and food chemistry
|November 18, 2025
概括
茄子种子的糖甘 (XG) 通过调节肠道细菌来改善小鼠的代谢健康. 这种植物多糖体显示出作为一种功能性食品成分的潜力,用于管理代谢障碍.
科学领域:
- * 营养科学 营养科学
- * 微生物学 微生物学
- *肠道微生物组研究
背景情况:
- *西黄糖 (XG) 是一种来自茄子种子的植物多糖,是FDA批准的食品添加剂.
- *虽然XG的结构已知,但其生理影响,特别是对代谢健康的影响,尚不清楚.
- * 人们越来越认识到肠道微生物群在代谢调节中的作用.
研究的目的:
- * 为了研究麻种子衍生型黄糖 (XG) 对代谢障碍的生理影响.
- *阐明肠道微生物群在XG作用中介作用.
- * 评估XG作为一种功能性食品成分对代谢健康的潜力.
主要方法:
- *使用了一种高脂肪饮食 (HFD) 诱导的胰岛素抵抗小鼠模型.
- *使用16SrRNA测序和代谢学来分析肠道微生物群和代谢概况.
- * 用便微生物群移植 (FMT) 和抗生素治疗来确认微生物群依赖的效果.
主要成果:
- *XG干预改善了HFD养小鼠的葡萄糖耐受性和肝功能.
- *XG减少了炎症和氧化应激,与改变的卡尼丁和二代谢有关.
- *肠道微生物群分析显示,在XG治疗后,Bifidobacterium的丰富.
- *XG的代谢益处可以通过FMT转移,并且依赖于完整的微生物群.
结论:
- * 塔米兰种子衍生的糖甘通过一种依赖肠道微生物群的机制减轻代谢障碍.
- *XG可以选择性地丰富有益的肠道细菌,如*Bifidobacterium*.
- *XG在功能性食品中显示出作为一种益生菌剂的潜力,用于代谢健康管理.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Glucagon-like Receptor Agonists
824
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
824
Dipeptidyl Peptidase 4 Inhibitors
566
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
566
Oral Hypoglycemic Agents: Biguanides and Glitazones
567
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
567


